Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

Grant unsuccessful. We missed submission of the human data by a week??!!

—————-

[color=red][/color]Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line

WAKEFIELD, MA – June 17, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory (RBL)............ Brilacidin has now demonstrated potent inhibition of SARS-CoV-2 in human lung and kidney cell lines, and in VERO cells, in laboratory testing conducted by independent academic researchers at two institutions........Testing results observed to date formed the basis for a federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin’s potential as a pan-coronavirus therapeutic, with possible extension into other viruses. The Company is in the process of manufacturing Brilacidin for intravenous (IV) dosing and will be seeking FDA guidance for a planned COVID-19 clinical study.

https://www.sec.gov/Archives/edgar/data/1355250/000147793220003469/ipix_ex991.htm

10-Q For the quarterly period ended: September 30, 2020

The Company is collaborating with a Regional Biocontainment Laboratory (RBL) for federal grants to fund continued research on Brilacidin as a treatment for SARS-CoV2. An earlier grant application was unsuccessful. At the time of that grant filing deadline, the only research data available was limited to non-human Vero cells. Subsequent to the filing, human cell line experiments were completed and the data is now available. Additional grant applications incorporating the new data are planned for submission before the end of 2020.

https://www.sec.gov/Archives/edgar/data/1355250/000147793220006561/ipix_10q.htm